Compare Elastic NV (ESTC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs State Street SPDR S&P Biotech ETF — how do they compare? Elastic NV trades at $98.23 (market cap $10.00B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Elastic NV and State Street SPDR S&P Biotech ETF are close in size by market cap, and Elastic NV is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ESTC | XBI | |
|---|---|---|
Market Cap | $10.00B | $10.11B |
Volume | 1,610,337 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $99.91 | $169.55 |
52-Week Low | $43.30 | $104.99 |
Typical Hold Time | 10 Days | 38 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $95.26, up 2.32% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches, including a new metrics platform and serverless vector database, highlight innovation in AI and observability. Revenue growth is projected to increase from $1.48B in 2025 to $1.8B in 2026, with net income turning positive to $376M.
The outlook is positive, driven by product momentum and earnings beats, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though the high target of $120.00 indicates upside potential. Investors should weigh strong fundamentals against valuation concerns and market volatility.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
